Green light for six new therapies in Scotland
Six therapies assessed by the Scottish
Medicines Consortium this month have been accepted for use within NHS Scotland.
Bondronat (ibandronate) receives a double endorsement — it can
be used for treatment of hypercalcaemia associated with cancer and also
to prevent skeletal events in patients with breast cancer and metastatic
bone disease.
Other treatments that were accepted for use were Velcade (bortezomib)
for multiple myeloma, Imigran Radis (sumatriptan succinate) for migraine
and Nexium (intravenous esomeprazole) for gastro-oesophageal reflux disease
when oral therapy is not appropriate.
OxyNorm (oxycodone) and Yentreve (duloxetine) received more cautious
welcomes and were accepted for restricted use. Oxycodone can be used
for the treatment of moderate to severe pain in patients with cancer
who have difficulty tolerating morphine or diamorphine therapy. Duloxetine
can be used as part of an overall management strategy for stress urinary
incontinence in addition to pelvic floor muscle training. |
The
Pharmaceutical Journal
Acrobat
Reader